Ask a clinical question and tap into Healio AI’s knowledge base.
November 10, 2025
2 min read
‘);
notification.css({
‘position’: ‘fixed’,
‘top’: ’20px’,
‘right’: ’20px’,
‘background’: ‘#373D3F’,
‘color’: ‘white’,
‘padding’: ’10px 15px’,
‘border-radius’: ‘5px’,
‘z-index’: ‘9999’,
‘font-size’: ’14px’,
‘box-shadow’: ‘0 2px 8px rgba(0,0,0,0.2)’
});
$(‘body’).append(notification);
// Fade out and remove after 3 seconds
setTimeout(function () {
notification.fadeOut(300, function () {
notification.remove();
});
}, 3000);
}
//# sourceURL=social.js
Key takeaways:
- Most women with PCOS treated with tirzepatide experienced 5% or more, 10% or more and 15% or more weight loss.
- Women engaged in a digital service achieved faster weight loss vs. unengaged women.
ATLANTA — More than 90% of women with polycystic ovary syndrome achieved at least 10% total weight loss after 10 months of tirzepatide treatment, according to findings presented at ObesityWeek.
“Typically, we would advise that patients should lose at least 5% of their total body weight to help improve symptoms of weight loss. So, that would be menstrual regularity, hirsutism and also the insulin resistance associated with their own development of nonreturn cardiometabolic conditions,” David R. Huang, BSc, MBBS, DRCOG, director of clinical innovation at Voy and research collaboration leader with Imperial College London, said during a presentation. “However, with the aspects of these new mass obesity medications, the microenvironment, the genetic environment, and lifestyle and behavior change is especially difficult for these patients to lose weight and maintain it, and we also know that, from SURMOUNT trials and some real-world evidence, that tirzepatide is extremely effective at encouraging significant weight loss.”
Huang and colleagues conducted a retrospective cohort study of 4,241 women living with PCOS (median age, 34 years; median BMI, 35.56 kg/m2) in the U.K. who were prescribed tirzepatide (Zepbound, Eli Lilly) between February 2024 and January 2025. All participants were part of a digital weight-loss service that included access to lifestyle coaching, weight tracking and other support tools. Researchers defined engagement as attending at least one lifestyle coaching session, regularly tracking weight with at least one entry per week and using the app at least once.
At 10 months, median weight loss was 18.81%. Women who were digitally engaged had greater weight loss compared with those who were unengaged (21.02% vs. 17.23%; P < .001).
After 10 months of tirzepatide treatment, 96.58% of women had 5% or more total weight loss, 90.8% had 10% or more total weight loss and 75.96% had 15% or more total weight loss. Digitally engaged women had faster time to achieve 5% or more, 10% or more and 15% or more total weight loss compared with unengaged women.
“[These findings] suggest that the use of digital tools in these patients could confer better weight-loss outcomes,” Huang said. “We’re really excited to explore further research looking at other complex metabolic conditions.”
‘);
notification.css({
‘position’: ‘fixed’,
‘top’: ’20px’,
‘right’: ’20px’,
‘background’: ‘#373D3F’,
‘color’: ‘white’,
‘padding’: ’10px 15px’,
‘border-radius’: ‘5px’,
‘z-index’: ‘9999’,
‘font-size’: ’14px’,
‘box-shadow’: ‘0 2px 8px rgba(0,0,0,0.2)’
});
$(‘body’).append(notification);
// Fade out and remove after 3 seconds
setTimeout(function () {
notification.fadeOut(300, function () {
notification.remove();
});
}, 3000);
}
//# sourceURL=social.js